Investment Thesis
Biomerica is a severely distressed diagnostic company with stagnant revenue ($2.6M), massive operating losses (-96.1% margin), and persistent cash burn (-$1.3M operating cash flow). Despite modest liquidity (3.25x current ratio), the company is operationally insolvent with no clear path to profitability or sustainable revenue growth.
Strengths
- Strong current ratio of 3.25x provides near-term liquidity buffer
- Zero long-term debt reduces financial leverage risk
- Cash position of $2.5M provides runway for operations
Risks
- Flat revenue with zero growth trajectory indicates severe market/competitive headwinds
- Negative operating margin of -96.1% indicates business model is fundamentally broken
- Persistent operating cash burn of -$1.3M will exhaust cash reserves within 1.9 years at current rate
- Net losses of -$1.3M on only $2.6M revenue demonstrates inability to control costs
- Low gross margin of 18.4% leaves minimal buffer for operating expenses
- Negative ROE and ROA show value destruction across equity and assets
Key Metrics to Watch
- Quarterly revenue trend - any indication of stabilization or contraction acceleration
- Operating cash flow depletion rate and runway to insolvency
- Gross margin sustainability and cost structure improvements
- Cash balance trajectory and potential need for financing or restructuring
- Form 4 insider trading activity patterns - selling suggests lack of confidence
Financial Metrics
Revenue
2.6M
Net Income
-1.3M
EPS (Diluted)
$-0.48
Free Cash Flow
-1.3M
Total Assets
6.0M
Cash
2.5M
Profitability Ratios
Gross Margin
18.4%
Operating Margin
-96.1%
Net Margin
-50.9%
ROE
-29.7%
ROA
-21.8%
FCF Margin
-50.6%
Balance Sheet & Liquidity
Current Ratio
3.25x
Quick Ratio
2.29x
Debt/Equity
0.00x
Debt/Assets
26.5%
Interest Coverage
-6,782.02x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-21T07:40:11.904434 |
Data as of: 2025-11-30 |
Powered by Claude AI